The grant is expected to fund two thirds of the development cost of the project.
Within this subsidized project, Activus will develop ophthalmic solutions that would differ from the existing treatments because they would be delivered to the posterior eye segment.
Up to two thirds of the development costs incurred for this project between 23 August 2011 and 28 February 2013 will be subsidized by the grant from NEDO.